Cystic Fibrosis clinical trials

The registry lists 1,621 studies for Cystic Fibrosis across more than 10 countries. 201 are recruiting or about to start. 1,451 of them are mainly about Cystic Fibrosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

ClinicalTrials.gov finds 1,784 studies for Cystic Fibrosis. How that becomes 1,619 here

This page counts the studies the registry files under Cystic Fibrosis, and those it files under no condition that list Cystic Fibrosisthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

1,784Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−17List Cystic Fibrosis as a condition, but the registry did not file them under itMost often written as “Cystic Fibrosis in Children” (4), “Cystic Fibrosis Liver Disease” (3), and “Cystic Fibrosis-related Diabetes” (3). The registry filed them under other conditions only, most often Exocrine Pancreatic Insufficiency (3) and Sinusitis (2).
−148Match it another way28 name it in the title, 1 in a keyword, and 119 by a synonym or other text the search reads.
1,619The count on this page36 of them list Cystic Fibrosis in their own words; the registry filed them under no condition.

Get an email when these change. Save the Cystic Fibrosis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 1,062
Recruiting: 156
Status unknown: 124
Terminated: 123
Active, not recruiting: 52
Withdrawn: 49

Phase

Phase 2: 254
Phase 1: 191
Phase 3: 174
Phase 4: 90
Early Phase 1: 14

Where

United States: 717
France: 251
United Kingdom: 235
Canada: 179
Germany: 147
Belgium: 118

Who runs them

Vertex Pharmaceuticals Incorporated (119) · Hospices Civils de Lyon (35) · Assistance Publique - Hôpitaux de Paris (31) · National Jewish Health (22) · Gilead Sciences (22) · University of North Carolina, Chapel Hill (20) · The Hospital for Sick Children (18) · University of Alabama at Birmingham (18)

What is being tested here

Drugs under test in Cystic Fibrosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Ivacaftor	4	45	82
Tezacaftor	4	25	43
Elexacaftor	2	19	23
Hyperpolarized Xe-129	2	0	7
Linaclotide	2	0	2
Albuterol	1	0	4
Losartan	1	0	3
Gallium nitrate	1	0	3
Gallium	1	0	3
Ceftolozane	1	0	2

Drug classes tested here Beta-lactamase inhibitors 1 open · Bronchodilators 1 open · PDE5 inhibitors 7 · DPP-4 inhibitors 6 · Proton pump inhibitors (PPIs) 3

Coming up

11phase 3 studies under way

78studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Apr 2027Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del · Phase 3 · Vertex Pharmaceuticals Incorporated
Jun 2027Maralixibat in Patients With Cystic Fibrosis and Constipation · Phase 3 · Children's Hospital Los Angeles
Jun 2027Bionic Pancreas in CFRD · Phase 3 · Jaeb Center for Health Research
Jul 2027Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy · Phase 3 · Indiana University
Sep 2027Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older · Phase 3 · Vertex Pharmaceuticals Incorporated
Nov 2026A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF · ReCode Therapeutics
Nov 2026Microbial Biomarkers of EArly Pseudomonas Aeruginosa Colonization in CHildren With Cystic Fibrosis · University Hospital, Brest
Nov 2026Early Check: Expanded Screening in Newborns · RTI International
Nov 2026Autogenic Drainage Versus Mechanical Percussion in Children With Cystic Fibrosis · Riphah International University
Dec 2026Personalized Mobile Health Platform to Promote Physical Activity in Adolescents and Young Adults With Cystic Fibrosis · Nemours Children's Clinic

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger. 86 (55%) take children under 18. 4 (3%) are for women only and 1 (1%) for men only; 41 (26%) take healthy volunteers.

Recruiting studies that take each age, of 156
Age	Women	Men
10	68 (44%)	67 (43%)
18	144 (92%)	141 (90%)
30	127 (81%)	124 (79%)
40	126 (81%)	123 (79%)
50	124 (79%)	121 (78%)
65	120 (77%)	117 (75%)
75	110 (71%)	107 (69%)
85	109 (70%)	106 (68%)

Across all 1,621 studies, recruiting or not: 38% stop at 75 or younger and 35% at 65; 62% take children; 3% are for women only and 1% for men only; 19% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Cystic Fibrosis studies take

Of 67 phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 26 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	10 mo5–34 · 62 studies	8 mo2–16 · 39 studies	—
Phase 1/2	24 mo14–46 · 26 studies	—	—
Phase 2	21 mo9–34 · 57 studies	15 mo7–29 · 40 studies	—
Phase 3	26 mo16–39 · 67 studies	25 mo14–36 · 58 studies	—
Phase 4	32 mo20–48 · 30 studies	—	—
Interventional, no phase	23 mo12–48 · 229 studies	—	24 mo12–48 · 214 studies
Observational	41 mo19–79 · 243 studies	—	40 mo19–89 · 228 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 15, 2026.

Show 5 more

Type 2 Inflammation in Adults With Cystic FibrosisOct 23, 2026NCT07892443
A Precision Medicine Approach to Assess Protein Function Loss and the Potential for CFTR Function Restoration in Cystic Fibrosis and Related DisordersOct 22, 2026NCT07889973
Management of Breast Fibroadenoma: Comparing Observation, Microwave Ablation, and Surgical ExcisionOct 22, 2026NCT07890766
PERCE-MUCO: Perceptions and Expectations of People With Cystic Fibrosis Regarding a Change in TreatmentOct 21, 2026NCT07885410
SPutum Induction and Nebuliser deviCEs for Patients With CFOct 19, 2026NCT07879651

Studies

Recruiting first, then most recently updated. Showing 50 of 1,621. Browse all 1,621 → or search them.